Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress

Viridian Therapeutics, Inc.\DE (VRDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress - $24.7 million in Lumvoa ™ (veligrotug-vvze) net product revenue with more than 100 patients on therapy at the end of Q3 2026 - - Elegrobart Biologics License

Event · Earnings
Original reporting
Published Nov 4, 2026, 12:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$VRDN
Neutral
high confidence
Mentioned
$VRDN
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VRDNNeutralMed
01

Why it matters

The earnings release provides fresh financial metrics and pipeline updates, informing short‑term pricing and longer‑term valuation.

02

Market read

First‑time quarterly disclosure with new revenue and cash figures; relevant for biotech traders assessing earnings quality and pipeline risk.

03

What to watch

Upcoming BLA submission for elegrobart and phase‑1 data for VRDN‑008 may provide upside catalysts beyond the earnings window.

Relevance 7/10Novelty 8/10Timing: pre‑market today after 8‑K filing
AlphAI · Earnings readVRDN · Third quarter 2026 · ended September 30, 2026

Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress

→Mixed quarter

Lumvoa generated first-quarter launch net product revenue of $24.7 million and more than 100 patients were on therapy, while research and development expense declined. However, total revenue declined against a prior-year period containing $70,000 in license revenue, selling, general and administrative expense increased to $57,609, and net loss widened to $101,209.

Revenue
25.8M
Lumvoa product revenue, net, three months ended September 30, 2026
$24.7M
EPS · GAAP
$ (0.81)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Product revenue, net, three months ended September 30, 2026 (in thousands)GAAP$24.67M––
License revenue, three months ended September 30, 2026 (in thousands)GAAP125K––
Collaboration revenue - related parties, three months ended September 30, 2026 (in thousands)GAAP956K––
Total revenues, three months ended September 30, 2026 (in thousands)GAAP25.75M––
Cost of revenues, three months ended September 30, 2026 (in thousands)GAAP1.53M––
Research and development, three months ended September 30, 2026 (in thousands)GAAP70.09M––
Selling, general and administrative, three months ended September 30, 2026 (in thousands)GAAP57.61M––
Total operating expenses, three months ended September 30, 2026 (in thousands)GAAP129.2M––
Loss from operations, three months ended September 30, 2026 (in thousands)GAAP−103.5M––
Total other income, net, three months ended September 30, 2026 (in thousands)GAAP2.27M––
Net loss, three months ended September 30, 2026 (in thousands)GAAP−$101.2M––
Net loss allocated to common stock, three months ended September 30, 2026 (in thousands)GAAP−$91.44M––
Net loss per share, basic and diluted, common stock, three months ended September 30, 2026GAAP$ (0.81)––
Weighted-average common shares outstanding, basic and diluted, three months ended September 30, 2026GAAP113,407,432––
Net loss allocated to Series A convertible preferred stock, three months ended September 30, 2026 (in thousands)GAAP−$7.16M––
Net loss per share, basic and diluted, Series A convertible preferred stock, three months ended September 30, 2026GAAP$ (53.76)––
Weighted-average Series A convertible preferred stock outstanding, basic and diluted, three months ended September 30, 2026GAAP133,191––
Net loss allocated to Series B convertible preferred stock, three months ended September 30, 2026 (in thousands)GAAP−$2.60M––
Net loss per share, basic and diluted, Series B convertible preferred stock, three months ended September 30, 2026GAAP$ (53.76)––
Weighted-average Series B convertible preferred stock outstanding, basic and diluted, three months ended September 30, 2026GAAP48,463––
Product revenue, net, nine months ended September 30, 2026 (in thousands)GAAP$24.67M––
License revenue, nine months ended September 30, 2026 (in thousands)GAAP364K––
Collaboration revenue - related parties, nine months ended September 30, 2026 (in thousands)GAAP1.14M––
Total revenues, nine months ended September 30, 2026 (in thousands)GAAP26.18M––
Cost of revenues, nine months ended September 30, 2026 (in thousands)GAAP1.53M––
Research and development, nine months ended September 30, 2026 (in thousands)GAAP219.3M––
Selling, general and administrative, nine months ended September 30, 2026 (in thousands)GAAP151.3M––
Total operating expenses, nine months ended September 30, 2026 (in thousands)GAAP372.1M––
Loss from operations, nine months ended September 30, 2026 (in thousands)GAAP−345.9M––
Total other income, net, nine months ended September 30, 2026 (in thousands)GAAP12.69M––
Net loss, nine months ended September 30, 2026 (in thousands)GAAP−$333.2M––
Net loss allocated to common stock, nine months ended September 30, 2026 (in thousands)GAAP−$296.5M––
Net loss per share, basic and diluted, common stock, nine months ended September 30, 2026GAAP$ (2.75)––
Weighted-average common shares outstanding, basic and diluted, nine months ended September 30, 2026GAAP107,875,408––
Net loss allocated to Series A convertible preferred stock, nine months ended September 30, 2026 (in thousands)GAAP−$24.61M––
Net loss per share, basic and diluted, Series A convertible preferred stock, nine months ended September 30, 2026GAAP$ (183.26)––
Weighted-average Series A convertible preferred stock outstanding, basic and diluted, nine months ended September 30, 2026GAAP134,263––
Net loss allocated to Series B convertible preferred stock, nine months ended September 30, 2026 (in thousands)GAAP−$12.10M––
Net loss per share, basic and diluted, Series B convertible preferred stock, nine months ended September 30, 2026GAAP$ (183.26)––
Weighted-average Series B convertible preferred stock outstanding, basic and diluted, nine months ended September 30, 2026GAAP66,004––

Segments

SegmentRevenueq/qy/y
Lumvoa product revenue, net, three months ended September 30, 2026More than 100 patients were on therapy with Lumvoa as of September 30, 2026; the company cited significant market access progress and continued execution across field sales, medical, market access, and patient services.$24.7M––
License revenue, three months ended September 30, 2026 (in thousands)Not disclosed.125K––
Collaboration revenue - related parties, three months ended September 30, 2026 (in thousands)Not disclosed.956K––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Q4 2026 and Q1 2027 outlook

  • NoteViridian expects to submit a BLA to the U.S. FDA for elegrobart in TED in Q1 2027.
  • NoteVRDN-292 IND on track to support phase 1 clinical trial initiation in Q4 2026, starting in patients with Graves’ disease.
  • NoteViridian expects to announce VRDN-008 phase 1 healthy volunteer data and development plans for the FcRn portfolio in Q4 2026.
  • NoteExisting cash and anticipated future commercial revenues from Lumvoa and elegrobart, if approved, are expected to be able to fund Viridian’s current business plans through profitability.

What drove it

  • Lumvoa generated $24.7 million in net product revenue during its first quarter of launch.
  • More than 100 patients were on therapy with Lumvoa at the end of Q3 2026.
  • Research and development expense decreased due to reduced expenses related to veligrotug and elegrobart clinical studies, partially offset by additional investment in the TSHR program and FcRn portfolio and increased personnel-related costs.
  • Selling, general and administrative expense increased due to personnel-related costs and professional services supporting Lumvoa commercial activities and the growing organization.
  • CMS assigned Lumvoa permanent J-code J3242, effective January 1, 2027.

Concerns

  • Net loss was $ (101,209) for the three months ended September 30, 2026, compared with $ (34,599) for the same period in 2025.
  • Selling, general and administrative expense was 57,609 for the three months ended September 30, 2026, compared with 24,322 for the same period in 2025 (in thousands).
  • Total revenues were 25,752 for the three months ended September 30, 2026, compared with 70,570 for the same period in 2025 (in thousands), when the company recorded 70,000 of license revenue.
  • The planned elegrobart BLA submission, the VRDN-292 phase 1 initiation, and VRDN-008 data disclosure remain forward-looking milestones.

What to watch

  • VRDN-008 phase 1 healthy volunteer data and development plans for the FcRn portfolio expected in Q4 2026.
  • VRDN-292 phase 1 clinical trial initiation in patients with Graves’ disease expected in Q4 2026.
  • Elegrobart BLA submission for TED expected in Q1 2027.
  • The January 1, 2027 effective date for Lumvoa permanent J-code J3242.
  • Lumvoa patient adoption, market access progress, and net product revenue following the first quarter of launch.

Balance sheet and cash flow

  • Cash, cash equivalents, and marketable securities: $ 955,206 as of September 30, 2026, compared with $ 874,652 as of December 31, 2025 (in thousands).
  • Accounts receivable, net: 29,782 as of September 30, 2026, compared with — as of December 31, 2025 (in thousands).
  • Other assets: 43,682 as of September 30, 2026, compared with 24,766 as of December 31, 2025 (in thousands).
  • Total assets: $ 1,028,670 as of September 30, 2026, compared with $ 899,418 as of December 31, 2025 (in thousands).
  • Total liabilities: 447,972 as of September 30, 2026, compared with 177,251 as of December 31, 2025 (in thousands).
  • Total stockholders’ equity: 580,698 as of September 30, 2026, compared with 722,167 as of December 31, 2025 (in thousands).
  • Total liabilities and stockholders’ equity: $ 1,028,670 as of September 30, 2026, compared with $ 899,418 as of December 31, 2025 (in thousands).
  • As of September 30, 2026, Viridian had 125,636,093 shares of common stock outstanding on an as-converted basis, including 113,525,222 shares of common stock and an aggregate 12,110,871 shares of common stock issuable upon conversion of 133,191 and 48,463 shares of Series A and Series B preferred stock, respectively.

Analysis

Viridian reported its first quarter of Lumvoa launch revenue, with net product revenue of $24.7 million and more than 100 patients on therapy as of September 30, 2026. Management highlighted market-access progress, continued commercial and medical execution, and the assignment of permanent J-code J3242 effective January 1, 2027. The company recorded no net product revenue in the comparable 2025 period.

Total revenues were 25,752 for the three months ended September 30, 2026, versus 70,570 in the prior-year period, in thousands. The year-ago period included 70,000 of license revenue, while current-quarter revenue was primarily product revenue. Collaboration revenue from related parties was 956 and license revenue was 125 in the current quarter, in thousands.

The expense mix reflects the commercial launch and ongoing pipeline investment. Research and development expense declined to 70,093 from 86,261, in thousands, driven by lower veligrotug and elegrobart clinical-study expenses, partly offset by TSHR and FcRn investment and higher personnel costs. Selling, general and administrative expense increased to 57,609 from 24,322, in thousands, due to personnel-related costs and professional services for Lumvoa commercial activities and organizational growth. Net loss widened to $ (101,209), compared with $ (34,599), in thousands.

Cash, cash equivalents, and marketable securities were $ 955,206 as of September 30, 2026, in thousands, compared with $ 874,652 as of December 31, 2025. Viridian stated that existing cash and anticipated commercial revenues from Lumvoa and elegrobart, if approved, are expected to fund current business plans through profitability. Near-term execution milestones are VRDN-008 phase 1 healthy-volunteer data and FcRn development plans, plus VRDN-292 phase 1 initiation, both expected in Q4 2026, followed by an elegrobart TED BLA submission expected in Q1 2027.

Management, verbatim

We are highly encouraged by the strength of Lumvoa’s early launch in TED, which has exceeded expectations.

Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics

Not in the filing

stated, not guessed
  • Gross profit and gross margin were not reported.
  • Non-GAAP revenue, earnings, EPS, or expense measures were not reported.
  • Prior-quarter financial comparisons were not reported.
  • Operating cash flow and free cash flow were not reported.
  • Debt was not reported.
  • Share repurchases and dividends were not reported.
  • A tax rate was not reported.
  • Quantitative forward revenue, gross-margin, operating-expense, or tax-rate guidance was not reported.
  • A previous outlook section was not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Viridian Therapeutics (Nasdaq: VRDN) is a biotech focused on thyroid eye disease, reporting its Q3 2026 results via SEC Form 8‑K.

Company-level read

Ticker impact

$VRDNNeutralHigh confidence
Context

Viridian Therapeutics filed an 8‑K reporting Q3 2026 results, including $24.7 M Lumvoa revenue and $955.2 M cash, plus upcoming BLA submission and trial milestones.

Expected impact

likely modest downside as investors weigh loss against revenue growth and cash position

Evidence & confidence

First‑time disclosure of quarterly numbers; revenue is modest but cash is ample, loss may prompt sell‑off.

Market effects

Biotech sector may see slight pullback as a peer reports a loss despite product launch revenue.

US biotech investors may adjust exposure; no broader regional effect.

Limited to biotech investors; no macro impact.

Counterpoint

The cash cushion and first‑quarter product revenue could support a rally if investors focus on runway rather than loss.

Key entities

  • Viridian Therapeutics

    Biotech firm developing treatments for autoimmune and rare diseases.

Every VRDN earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$VRDNMedAI 8/10

Viridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies says

Jefferies highlights Viridian Therapeutics' (VRDN) VRDN-008 as a potential best-in-class FcRn inhibitor, with an extended half-life supporting eight-week dosing. Phase I results showed a 74% peak IgG reduction sustained for eight weeks. The company plans to start a registrational study in gMG in mid-2027, with potential approval by 2031. Jefferies maintains a $35 price target, excluding contributions from VRDN's broader pipeline.

$VRDNMedAI 8/10

Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing

Viridian Therapeutics, Inc.\DE (VRDN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing - VRDN-008, a half-life extended FcRn inhibitor, demonstrated deep and sustained IgG reduction through 8 weeks after sub

$VRDNHighAI 8/10

Viridian reports phase 1 results for VRDN-008 autoimmune drug

Viridian Therapeutics (VRDN) reported phase 1 trial results for VRDN-008, showing a 74% reduction in IgG and a half-life of 15-18 days. No serious adverse events were observed. The company plans to start pivotal trials in 2027, targeting myasthenia gravis first. VRDN-008 will be administered using Enable Injections’ enFuse device, licensed exclusively by Viridian.